Anugerah 88 Logo
$9.01+0.10|(+1.12%)
52W H: 12.5852W L: 6.47Beta: -0.12

About Xilio Therapeutics Inc

Frequently Asked Questions

What is the 52-week range for XLO?

The 52-week high is $12.58 and the 52-week low is $6.47.

What is the P/E ratio for XLO?

The P/E ratio data is currently unavailable.

What is the dividend yield for XLO?

This company does not currently pay a dividend or the data is unavailable.

What is the Return on Equity (ROE)?

The trailing twelve months (TTM) Return on Equity is -9.23%.

What is the Net Profit Margin?

The Net Profit Margin (TTM) is -34.06%.

What is the Price to Book (P/B) Ratio?

The annual Price to Book ratio stands at 0.95.

Analyst Recommendation Trends

Wall Street analyst consensus for XLO over the last few months:

2026-09-01
Buy: 2
S.Buy: 2
Hold: 1
Sell: 0
2026-08-01
Buy: 2
S.Buy: 2
Hold: 1
Sell: 0
2026-07-01
Buy: 2
S.Buy: 2
Hold: 1
Sell: 0
2026-06-01
Buy: 2
S.Buy: 2
Hold: 1
Sell: 0

Latest XLO News

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective October 1, 2026, the company granted non-qualified stock options to purchase an aggregate of 100,895 shares of its common stock to two new employees under Xilio Therapeutics’ Third Amended and Restated 2022 Inducement Stock Incentive Plan (the 2022

Yahoo10/2/2026

Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncologyWALTHAM, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the appointment of Dr. Yariv Houvras as chief medical officer. “We are thrill

Yahoo9/28/2026

Related Stocks (Peers)

Companies operating in similar sectors to XLO:

ACETBOLDKLRSCNTBCLNNXLOINMBEXOZCELU950160.KQ

Recent Insider Transactions

DateNameShares ChangedPriceValue
2026-10-01Houvras Yariv+105,000--
2026-06-11Curran Daniel J.+5,000--
2026-06-11Bello Akintunde Olatokumbo+5,000--
2026-06-11Xu Yuan+5,000--
2026-06-11ROSS ROBERT W.+5,000--
2026-06-11Brennan Aoife+5,000--
2026-06-11Bonstein Sara+5,000--
2026-06-11Shannon James Samuel+5,000--
2026-04-15Blanchard Cheryl R+10,000--
2026-03-26Shannon James Samuel+5,000$8.79$43,950
2026-02-13GILEAD SCIENCES, INC.+3,739,000$0.5349$1,999,991
2026-01-02Brennan Kevin M.-1,826$0.6432$1,174
2026-01-02Frankenfield Christopher James-7,030$0.6432$4,522
2026-01-01Luptakova Katarina-16,625--
2026-01-01Luptakova Katarina+16,625--
2026-01-01Brennan Kevin M.-5,000--
2026-01-01Brennan Kevin M.+5,000--
2026-01-01Frankenfield Christopher James-19,375--
2026-01-01Frankenfield Christopher James+19,375--
2026-01-01Russo Rene-44,250--
2026-01-01Russo Rene+44,250--
2025-12-31Luptakova Katarina+451,885--
2025-12-31Brennan Kevin M.+95,221--
2025-12-31Frankenfield Christopher James+668,789--
2025-12-31Russo Rene+1,500,258--
2025-11-26GILEAD SCIENCES, INC.-13,335,000--
2025-11-26GILEAD SCIENCES, INC.+13,335,000$0.7499$9,999,917
2025-11-21Brennan Kevin M.+20,000--
2025-11-21Brennan Kevin M.-20,000--
2025-11-21Brennan Kevin M.+25,000--
2025-11-21Brennan Kevin M.-25,000--
2025-11-21Brennan Kevin M.+55,000--
2025-11-21Brennan Kevin M.-55,000--
2025-11-21Brennan Kevin M.+131,700--
2025-11-21Luptakova Katarina+106,000--
2025-11-21Luptakova Katarina-106,000--
2025-11-21Luptakova Katarina+25,000--
2025-11-21Luptakova Katarina-25,000--
2025-11-21Luptakova Katarina+35,000--
2025-11-21Luptakova Katarina-35,000--
2025-11-21Luptakova Katarina+15,000--
2025-11-21Luptakova Katarina-15,000--
2025-11-21Luptakova Katarina+44,210--
2025-11-21Luptakova Katarina-44,210--
2025-11-21Luptakova Katarina+625,000--
2025-11-21Frankenfield Christopher James+300,000--
2025-11-21Frankenfield Christopher James-300,000--
2025-11-21Frankenfield Christopher James+150,000--
2025-11-21Frankenfield Christopher James-150,000--
2025-11-21Frankenfield Christopher James+117,000--
2025-11-21Frankenfield Christopher James-117,000--
2025-11-21Frankenfield Christopher James+20,000--
2025-11-21Frankenfield Christopher James-20,000--
2025-11-21Frankenfield Christopher James+45,000--
2025-11-21Frankenfield Christopher James-45,000--
2025-11-21Frankenfield Christopher James+37,296--
2025-11-21Frankenfield Christopher James-37,296--
2025-11-21Frankenfield Christopher James+23,786--
2025-11-21Frankenfield Christopher James-23,786--
2025-11-21Frankenfield Christopher James-155,090--
2025-11-21Frankenfield Christopher James-155,090--
2025-11-21Frankenfield Christopher James+925,000--
2025-11-21Russo Rene+700,000--
2025-11-21Russo Rene-700,000--
2025-11-21Russo Rene+350,000--
2025-11-21Russo Rene-350,000--
2025-11-21Russo Rene+150,000--
2025-11-21Russo Rene-150,000--
2025-11-21Russo Rene+100,000--
2025-11-21Russo Rene-100,000--
2025-11-21Russo Rene+50,041--
2025-11-21Russo Rene-50,041--
2025-11-21Russo Rene+135,134--
2025-11-21Russo Rene-135,134--
2025-11-21Russo Rene+473,334--
2025-11-21Russo Rene-473,334--
2025-11-21Russo Rene+239,703--
2025-11-21Russo Rene-239,703--
2025-11-21Russo Rene+2,075,000--